

Edgar Filing: INTROGEN THERAPEUTICS INC - Form 8-K

INTROGEN THERAPEUTICS INC  
Form 8-K  
August 23, 2002

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 23, 2002 (August 16, 2002)  
-----

Introgen Therapeutics, Inc.  
-----

(Exact name of registrant as specified in its charter)

|   |                             |                                      |
|---|-----------------------------|--------------------------------------|
| Delaware  | 0-21291                     | 74-2704230                           |
| -----   | -----                       | -----                                |
| (State or other jurisdiction<br>of incorporation) | (Commission<br>File Number) | (IRS Employer<br>Identification No.) |
| 301 Congress Avenue, Suite 1850, Austin, Texas    |                             | 78701                                |
| -----   | -----                       | -----                                |
| (Address of principal executive offices)          |                             | (Zip Code)                           |

Registrant's telephone number, including area code: (512) 708-9310  
-----

-----  
(Former name or former address, if changed since last report)

ITEM 5. OTHER EVENTS.

On August 16, 2002, Elise Wang resigned from the Board of Directors of Introgen Therapeutics, Inc. (the "Company"). Ms. Wang had served as a director of the Company since January 2001, and had also served as a member of the Audit Committee of the Board of Directors during that period. The Company issued a press release on August 23, 2002 regarding this matter, which is filed as Exhibit 99.1 to this Current Report on Form 8-K. The contents of such Exhibit are incorporated herein by reference.

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits.

99.1 Press Release dated August 23, 2002.

Edgar Filing: INTROGEN THERAPEUTICS INC - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 23, 2002

INTROGEN THERAPEUTICS, INC.

/s/ THOMAS G. FINNEGAN

-----  
Thomas G. Finnegan, Vice President

-2-

INDEX TO EXHIBITS

| Exhibit<br>Number<br>----- | Description of Document<br>-----     |
|----------------------------|--------------------------------------|
| 99.1                       | Press Release dated August 23, 2002. |